Drug
Vustanaciclib clinical trials
Also written RGT-419B.
- studies test it
- 3
- open now
- 2
- in phase 3
- 0
- first study started
- 2022
Keep track of what changes. Save the Vustanaciclib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Regor Pharmaceuticals Inc. (2) · Genentech, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Vustanaciclib is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruitingPhase 1/2Genentech, Inc.NCT07100106Written as GDC-4198
- FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast CancerRecruitingPhase 1Regor Pharmaceuticals Inc.NCT05304962Written as RGT-419B
- A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid TumorsActive, not recruitingPhase 1Regor Pharmaceuticals Inc.NCT06299124Written as RGT-419B